5th European Update Congress in NephrologyVienna, 10 – 11 September 2021

Nephro Update Europe 2021

Scientific Co-ChairsKai-Uwe Eckardt, GermanyTon Rabelink, Netherlands

National ChairRenate Klauser-Braun

www.nephro-update-europe.eu

Save 100 €

for 2022!

© A

. Kar

nhol

z/Fo

tolia

.com

The Update ConceptHigh ValueHighly qualifi ed and reputable speakers provide unbiased interpretation of the latest study results.

CompleteThe entire medical fi eld is covered in 13 sessions. You will be up-to-date in your speciality within two days.

Cutting-edge clinical studiesOnly international studies published in peer-reviewed journals during the past 12 months are presented. No repetition of existing state-of-the-art knowledge.

Ensured practical relevanceAll research results are evaluated by experts and put into perspective for your clinical and practical work – including clear-cut Take-Home Messages.

InteractivityInteraction among the participants is part of the concept: there is plenty of room for discussion with the speakers during each lecture and during breaks.

Extensive seminar materialEvery delegate receives a complete seminar compendium containing all of the scientifc presentations for future reference.

OOO

RRRIIIGGGIIINNNAAALLL

SSSUUUUUUPPPEEERRR IIIOOORRR MMMEEEDDDIIICCC AAA

LLL TTTRRR

AAAIII NNN

III NNNNNNNNNGGGGGG

Dear Colleagues and Friends,Welcome to the 5th Nephro Update Europe!

At med update europe, we have been providing top-notch, high-quality educational meetings for medical practitioners to learn, interact and exchange with each other, for over almost a decade.

Again this year, you can expect a proven concept where clinicians, as well as specialists, will receive a comprehensive, cutting-edge update of recent developments in the fi eld.

Leading European experts will provide you with critical analyses of latest research, as well as recommendations for your daily practice, along with many interaction opportunities … all unbiased and not infl uenced by industry.

Take the opportunity to join open discussions during the lectures, interact with speakers after their sessions in the Speaker’s Corners or via livechat through the livestream, and view the ePosters online or on the terminal on-site.

And don’t forget to attend the industry-sponsored symposia: Managing the Hypertension Patient: Is there a role for renal denervation? (Friday) and The new patient journey: Current and future management approaches to SHPT and CKD-aP (Saturday).

Last, but not least, thank you to our Partners: Vifor Fresenius Medical Care Renal Pharma Ltd., Medtronic, Boehringer Ingelheim/Lilly Diabetes Alliance and Hansa Biopharma. We couldn‘t do it without you!

Sincerely,

Kai-Uwe Eckardt A. J. (Ton) Rabelink

Scientific Co-Chairs

Kai-Uwe Eckardt (Germany)

A. J. (Ton) Rabelink (Netherlands)

Welcome (doors open and registration starts at 8:00) 9:15

GlomerulonephritisJack Wetzels, Netherlands

• Membranous nephropathy• IgA nephropathy• Minimal change disease/focal segmental glomerulosclerosis

9:30

Chronic Kidney DiseaseKai-Uwe Eckardt, Germany

• Defi nition and stages of CKD• Risk factors for development and progression of CKD• Complications and co-morbidities of CKD

10:15

Speaker‘s Corner – Break 11:00

Bone and Mineral DiseaseAdrian Covic, Romania

• Vascular calcifi cations• Calciproteins• News on FGF23 and Klotho

11:30

Acid Base DisordersEwout Hoorn, Netherlands

• Physiology and pathophysiology • Metabolic acidosis and outcomes• Treatment of metabolic acidosis in chronic kidney disease

12:15

Industry-sponsored Symposium 13:05

Speaker‘s Corner – Lunch Break 13:50

160140

120

300

100

280

80 260

60

240

40

220

20

200

0

180

mmHg

HypertensionTon Rabelink, Netherlands

• Covid & hypertension • Pharmacotherapy• Neurovascular damage

14:45

Cardiovascular DiseaseDanilo Fliser, Germany

• SGLT2-inhibition• Mineralocorticoid-receptor antagonists• Infl ammation and cardiovascular disease • COVID19 and RAAS-inhibition

15:30

Speaker‘s Corner – Break 15:30

Systemic Autoimmune DiseasesCharles Pusey, UK

• Anti-GBM disease • ANCA-associated vasculitis• Lupus nephritis

16:45

Welcome Reception 17:30

Program – Friday, 10 September

Program – Saturday, 11 September

Treatment of Kidney Failure I: Hemodialysis, Nutrition and Medical Therapy in Hemodialysis PatientsDenis Fouque, France

• Acidosis treatment• CKD managment, Nutrition guidelines• Arteriovenous fi stulas• SARS-CoV-2 vaccination

9:00

Treatment of Kidney Failure II: Infectious Complica-tions in Hemodialysis and Peritoneal DialysisAn De Vriese, Belgium

• Immune Response to SARS-CoV-2 Infection and Vaccination• Catheter-Related Bloodstream Infections• Clostridioides diffi cile Infection

9:45

Speaker‘s Corner – Break 10:30

Diabetic NephropathyHiddo Lambers Heerspink, Netherlands

• Trends in the prevalence and incidence of adverse outcomes • Pharmacotherapy: Latest trials• Emerging insights: Diabetic Kidney Disease and COVID-19

11:00

TransplantationRainer Oberbauer, Austria

• Donor – COMPARE (O2perfusion)• SARS-CoV2 Pandemic –> Kidney Transplantation• B-cell/humoral (ABMR - CD38, Carfi lzomib, Imlifi dase, Iptacopan)• T-cell (BK, CMV, Allo, exhaustion, TCR, Trex, CAR-T), • Cell based therapies (Trex, One Study, Car-T Phili)• Cancer immunotherapy & TX, Abata/CTLA-4 Inh, PD1-Inh• Prediction (iBox, AI, Biomarkers, etc)• Diagnostics Single cell • Outcomes: PROMs

11:45

Industry-sponsored Symposium 12:35

Speaker‘s Corner – Lunch Break – ePoster Awards 13:20

Acute Kidney Injury - PathophysiologySophie de Seigneux, Switzerland

• The AKI to CKD transition• Recent developments in AKI pathophysiology• Mitochondrial dysfunction• The metabolic switch in AKI

14:00

Acute Kidney Injury - ClinicalPatrick Murray, Ireland

• AKI Diagnosis & Staging• AKI Prevention & Therapy in High Risk Populations• Renal ReplacementTherapy in AKI

14:45

Speaker‘s Corner – End of Congress 15:30

Nephro Update Europe 2021 has been granted 10 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Speakers

Jack WetzelsProfessor of Nephrology

Department of Nephrology, Radboud University Nijmegen, Netherlands

Kai-Uwe EckardtProfessor of Nephrology, Head of the Department of Nephrology and Medical Intensive Care

Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Germany

Adrian CovicProfessor of Nephrology and Internal Medicine, Director of the Nephrology Clinic and the Dialysis and Transplantation Center

Dialysis and Transplantation Center, »Grigore T. Popa« University of Medicine & Pharmacy, Iasi, Romania

Ewout HoornProfessor of Nephrology

Erasmus Medical Center, Rotterdam, Netherlands

A. J. (Ton) RabelinkProfessor and Chair of Medicine, Head of the Division of Nephrology and the Einthoven Laboratory for

Experimental Vascular Medicine

Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands

Danilo FliserProfessor of Medicine, Head of the Department of Internal Medicine IV (Renal & Hypertensive Disease)

Saarland University Medical CentreHomburg/Saar, Germany

Charles PuseyProfessor of Medicine, Head of the Renal & Vascular Infl ammation Section

Department of Immunology and Infl ammationSection, Imperial College London, UK

Denis FouqueProfessor of Nephrology, Associate Chief of the Divisi-on of Nephrology

Division of Nephrology, University Claude Bernard Lyon 1 & Centre Hospitalier Lyon Sud, Villeurbanne, France

An De VrieseProfessor of Internal Medicine, Head of the Depart-ment of Internal Medicine and of the Division of Nephrology and Infectious Diseases

Division of Nephrology and Infectious Diseases, AZ Sint-Jan Bruge, Belgium

Hiddo Lambers HeerspinkProfessor of Clinical Pharmacology

Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, Netherlands

Rainer OberbauerProfessor of Medicine, Director of the Department of Nephrology & Dialysis and Transplant Medicine

Department of Nephrology & Dialysis and Transplant Medicine, Medical University of Vienna, Austria

Sophie de SeigneuxAssistant Professor of Medicine

Department of Nephrology, University Hospital of Geneva, Switzerland

Patrick MurrayProfessor of Clinical Pharmacology

UCD Catherine McAuley

Education & Research Centre, Dublin,

A. J. (Ton) RabelinkProfessor and Chair of Medicine, Head of the Division of Nephrology and the Einthoven Laboratory for

Experimental Vascular Medicine

Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands

Danilo FliserProfessor of Medicine, Head of the Department of Internal Medicine IV (Renal & Hypertensive Disease)

Saarland University Medical CentreHomburg/Saar, Germany

Charles PuseyProfessor of Medicine, Head of the Renal & Vascular Infl ammation Section

Department of Immunology and Infl ammationSection, Imperial College London, UK

Denis FouqueProfessor of Nephrology, Associate Chief of the Divisi-on of Nephrology

Division of Nephrology, University Claude Bernard Lyon 1 & Centre Hospitalier Lyon Sud, Villeurbanne, France

View a selection of Nephro Update Europelectures on-demand, whereever and whenever you want – free for delegates!

How it works:

• Register at www.streamed-up.com for free

• From the left-hand menu, choose European Update Congresses

• Find the video that you want to see and enter the code: NephroEurope21 (code is only accessible to 2021 delegates) 4 – 6 weeks after the event)

KI2

0280

_210

x148

karger.com/nephrology

NephrologySymplicity Spyral™

Renal Denervation System

Clinically Meaningful BP ReductionAcross 7,000 Patients*1,2

Learn more about Medtronic Renal Denervation for Uncontrolled Hypertension

* Patients enrolled in Medtronic-sponsored, funded or physician-initiated studies. 1. Lewington S. The Lancet. 2002;360(9349):1903-1913.2. Data on file, Medtronic. April 2021.

UC202201926aEE © Medtronic 2021.All rights reserved.

UC202201936EE © Medtronic 2021. All rights reserved.

Managing the Hypertension Patient: is there a role for renal denervation?Friday 10 September, 13:05 - 13:50Prof. Flavio Ribichini, Dr. Jose Antonio Garcia-Donaire

JOIN OUR SYMPOSIUM

Sans titre-4 1 27/08/2021 12:03

KI2

0280

_210

x148

karger.com/nephrology

NephrologySymplicity Spyral™

Renal Denervation System

Clinically Meaningful BP ReductionAcross 7,000 Patients*1,2

Learn more about Medtronic Renal Denervation for Uncontrolled Hypertension

* Patients enrolled in Medtronic-sponsored, funded or physician-initiated studies. 1. Lewington S. The Lancet. 2002;360(9349):1903-1913.2. Data on file, Medtronic. April 2021.

UC202201926aEE © Medtronic 2021.All rights reserved.

UC202201936EE © Medtronic 2021. All rights reserved.

Managing the Hypertension Patient: is there a role for renal denervation?Friday 10 September, 13:05 - 13:50Prof. Flavio Ribichini, Dr. Jose Antonio Garcia-Donaire

JOIN OUR SYMPOSIUM

Sans titre-4 1 27/08/2021 12:03

Present

Sponsored by

THE NEW PATIENT JOURNEY: NEPHRO UPDATE EUROPE 2021VIENNA AND VIRTUAL

Current and future management approaches to SHPT and CKD-aPSaturday 11 September 2021, 12.30–13.15 CEST

Extended-release calcifediol (ERC) in patients with non-dialysis-dependent CKD: a new answer to an old dilemmaSpeaker: Prof James Wetmore, USA

New frontiers for dialysis patients with CKD-associated pruritus: addressing unmet needs with difelikefalin (DFK)Speaker: Prof Juan Buades, Spain

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the congress organiser to hold the symposium.

© 2021 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved. Date of preparation: August 2021. HQ-RAY-2100049

To explore SHPT, its treatment challenges

and more, visit: SHPTchallenges.com

VIF1063 Nephro update 2021 A5 Ad #2.indd 1 26/08/2021 16:20

Date of preparation: July 2019 © 2019 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved.

HQ-RAY-1900019

Advancing hyperkalaemia and SHPT management in CKD

Friday, September 20, 2019; 16:45 - 17:45

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on the choice of topic and content. Payment has been made to the congress organizer to hold the symposium.

NEPHRO UPDATE EUROPE 2019

National House of Vinohrady, Prague, Czech Republic

● Optimizing RAASi therapy in ND-CKD patients through hyperkalaemia management

Speaker: Prof. Hermann Haller, Germany

● Current concepts for the management of SHPT in ND-CKD patients

Speaker: Prof. David Goldsmith, UK

PARTNER OF CHOICEFOR PHARMACEUTICALS AND INNOVATIVE PATIENT-FOCUSED SOLUTIONS

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care.

Vifor Pharma Group holds a central position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma.

viforpharma.com

COMPANYPROFILE

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).

For more information, please visit viforpharma.com

VIF1063 Nephro update 2021 A5 Ad #2.indd 2VIF1063 Nephro update 2021 A5 Ad #2.indd 2 26/08/2021 16:2026/08/2021 16:20

Present

Sponsored by

THE NEW PATIENT JOURNEY: NEPHRO UPDATE EUROPE 2021VIENNA AND VIRTUAL

Current and future management approaches to SHPT and CKD-aPSaturday 11 September 2021, 12.30–13.15 CEST

Extended-release calcifediol (ERC) in patients with non-dialysis-dependent CKD: a new answer to an old dilemmaSpeaker: Prof James Wetmore, USA

New frontiers for dialysis patients with CKD-associated pruritus: addressing unmet needs with difelikefalin (DFK)Speaker: Prof Juan Buades, Spain

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the congress organiser to hold the symposium.

© 2021 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved. Date of preparation: August 2021. HQ-RAY-2100049

To explore SHPT, its treatment challenges

and more, visit: SHPTchallenges.com

VIF1063 Nephro update 2021 A5 Ad #2.indd 1 26/08/2021 16:20

Date of preparation: July 2019 © 2019 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved.

HQ-RAY-1900019

Advancing hyperkalaemia and SHPT management in CKD

Friday, September 20, 2019; 16:45 - 17:45

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on the choice of topic and content. Payment has been made to the congress organizer to hold the symposium.

NEPHRO UPDATE EUROPE 2019

National House of Vinohrady, Prague, Czech Republic

● Optimizing RAASi therapy in ND-CKD patients through hyperkalaemia management

Speaker: Prof. Hermann Haller, Germany

● Current concepts for the management of SHPT in ND-CKD patients

Speaker: Prof. David Goldsmith, UK

PARTNER OF CHOICEFOR PHARMACEUTICALS AND INNOVATIVE PATIENT-FOCUSED SOLUTIONS

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care.

Vifor Pharma Group holds a central position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma.

viforpharma.com

COMPANYPROFILE

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).

For more information, please visit viforpharma.com

VIF1063 Nephro update 2021 A5 Ad #2.indd 2VIF1063 Nephro update 2021 A5 Ad #2.indd 2 26/08/2021 16:2026/08/2021 16:20

Nephro Update Europe 2022 – 9-10 September, Amsterdam (Nordwijk)

It is our pleasure to announce the 6th Nephro Update Europe – reserve a space now and save 100€!

Meet up with colleagues and friends while receiving a complete update in all areas of nephrology.

To stay updated follow us on twitter @medupdateeurope

or visit our website: www.medupdate-europe.eu

Congress Host

med update europe GmbHHagenauer Straße 53, D-65203 WiesbadenPhone: + 49 (0) 611 9 45 87 99 - 0 Fax: + 49 (0) 611 9 45 87 99 - 9info@medupdate-europe.eu www.medupdate-europe.eu

Registration includes:

• Participation in all lectures and symposia

• Seminar compendium (print or electronic)

• Catering during the congress

• Welcome reception on Friday evening

• Presentations to download and a selection of videos to view after the congress

LocationAustria Trend Hotel SavoyenRennweg 16, 1030 Vienna, Austria

Congress Organisationwikonect GmbHHagenauer Straße 53, D-65203 WiesbadenPhone: + 49 (0) 611 94 91 54-45, Fax: + 49 (0) 611 94 91 54-99nephro-update-europe@wikonect.de, www.wikonect.de

Useful Information

The following companies disclose their support in accordance with the FSA Code or with internal transparency rules: Vifor Fresenius Medical Care Renal Pharma Ltd., Medtronic, Boehringer Ingelheim/Lilly Diabetes Alliance and Hansa Biopharma. The support may entitle companies to a mention on the printed materials, hosting a symposium and an exhibition stand at the event. For more details see www.nephro-update-europe.eu. The sponsoring companies have no influence on the content or program of the meeting.